Tempus Next Cardiology

Tempus Next Cardiology is an AI-enabled care pathway intelligence platform designed to help clinicians identify and address undertreated cardiovascular disease. Built for providers and health systems, the platform empowers care teams to deliver the next step in a patient's care journey by surfacing deep, actionable insights from multimodal and longitudinal patient data — including medical imaging, EHR data, clinician notes, and time series data — and delivering customized notifications directly within established clinical workflows.

Tempus Next uses artificial intelligence to close care gaps by identifying patients who have not received treatment consistent with applicable clinical guidelines. The platform currently powers more than 150 hospitals nationwide, has screened over 2.5 million patients, and is connected to more than 350 EHR-integrated health systems across 2,000+ hospitals, screening more than 60,000 patients per month across 15 cardiovascular disease areas using 40+ algorithms.

Core Platform Capabilities

• Identify and contextualize patients in their care journey: AI-enabled solutions surface deep insights from multimodal, longitudinal patient data including medical imaging, EHR data, clinician notes, and time series data.
• Surface precision care pathways at the point of care: Tiered and customized notifications consistent with precision medicine guidelines are delivered within the clinician's existing workflow to reduce alert fatigue.
• Track patients for timely follow-up: Patient Tracking tools help manage current patient care effectively, Patient Lists enable search for specific patient groups, and dashboards provide insights into a hospital's broader patient population.
• Increase equitable access to care: The platform helps clinicians deliver timely and accurate diagnostics, procedures, and therapies for all patients regardless of socioeconomic status. Published research has demonstrated that use of Tempus Next reduced average time from index echocardiogram to follow-up for Black patients from 120 to 64 days, narrowing the gap relative to the overall patient population.

Disease Areas Covered

• Aorta: Tempus Next includes screening algorithms for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) using clinician reports from abdominal ultrasounds and CTs, alongside all other available patient data. The system provides guideline-driven notifications and follows patients through progression from low to high severity.
• Structural Heart: Screening capabilities cover appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation. Guideline-driven notifications help providers close care gaps across these populations.
• Cardiomyopathies: Screening protocols address non-ischemic dilated cardiomyopathy and cardiac oncologic disease. The platform aims to shorten time to referral for advanced heart failure treatment options such as left ventricular assist devices or heart transplants, and enables clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists based on guidelines.
• Electrophysiology: Capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States, yet fewer than 10% of patients who meet AHA/ACC/HRS criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device — with women more likely to be undertreated. Tempus Next continuously monitors patient data to identify at-risk patients and alerts care teams to guideline-based follow-up needs or disease progression.
• Guideline Directed Medical Therapies (GDMT): The platform screens for congestive heart failure and ischemic heart diseases, monitoring length of time and patient adherence to GDMT as well as key markers such as ejection fraction to determine potential need for referral to a heart clinic. Studies have shown that patients not optimized on GDMT are 26% more likely to have higher annualized healthcare utilization and emergency department visits.

Clinical Evidence and Case Studies

• A partnership with St. Francis, a specialty designated cardiac and heart valve center, demonstrated how Tempus Next enabled guideline-directed care for patients with structural heart disease.
• At Boulder Community Health, Tempus Next's AI-powered care pathway platform helped ensure timely, guideline-directed treatment for critical heart valve disease, transforming patient outcomes.
• At a large academic medical center, Tempus Next leveraged AI to address racial disparities in cardiac care, significantly improving follow-up times for patients with severe aortic stenosis and severe mitral regurgitation.
• Published scientific research supported by the platform spans topics including pulmonary hypertension phenotyping, aortic stenosis disease progression prediction, machine learning analysis of tricuspid regurgitation, sudden cardiac arrest risk identification, and the use of natural language processing for cardiac transthyretin amyloidosis diagnosis.

Tempus Next Cardiology integrates directly with EHR systems across more than 2,000 hospitals, enabling seamless deployment within existing clinical workflows. The platform is designed to support health equity, reduce diagnostic delays, and help providers deliver personalized, guideline-consistent cardiovascular care at scale.